Leniolisib, sold under the brand name Joenja, is a medication used for the treatment of activated phosphoinositide 3-kinase delta syndrome. It is a kinase inhibitor that is taken by mouth.
The most common side effects include headache, sinusitis, and atopic dermatitis.
Leniolisib was approved for medical use in the United States in March 2023. It is the first approved medication for the treatment of activated PI3K delta syndrome. The US Food and Drug Administration considers it to be a first-in-class medication. In 2025 NICE approved it for use in the British NHS. From Wikipedia
